ICA1L: A Potential Drug Target and Biomarker for Amyotrophic Lateral Sclerosis

Target Name: ICA1L

NCBI ID: G130026

ICA1L

Other Name(s): Amyotrophic lateral sclerosis 2 chromosomal region candidate gene 14 protein | Amyotrophic lateral sclerosis 2 chromosomal region candidate gene 15 protein | islet cell autoantigen 1 like | islet cell autoantigen 1,69kDa-like | amyotrophic lateral sclerosis 2 chromosomal region candidate gene 15 protein | ICA1L variant 1 | Amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 14 | amyotrophic lateral sclerosis 2 chromosomal region candidate gene 14 protein | Islet cell autoantigen 1-like protein | Ica69-related protein | amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 15 | ALS2CR14 | Amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 15 | amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 14 | ICA1L_HUMAN | ALS2CR15 | Islet cell autoantigen 1-like protein (isoform 1) | Islet cell autoantigen 1 like, transcript variant 1

ICA1L: A Potential Drug Target and Biomarker for Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease characterized by the progressive loss of motor neurons. It is one of the most common adult-onset progressive neurodegenerative diseases and its incidence is increasing with the aging population. The ALS is caused by the progressive loss of dystrophin, a protein that helps maintain muscle strength and function. The disease is usually fatal and there is currently no cure.

The ICA1L gene, located on chromosome 14, has been identified as a potential drug target and biomarker for ALS. ICA1L is a protein that is expressed in various tissues and cells, including muscle cells, nerve cells, and brain cells. It is known to play a role in the development and progression of ALS, and it is thought to contribute to the neurodegeneration that occurs in the disease.

ICA1L is a transmembrane protein that is expressed in the cytoplasm of muscle cells. It is composed of four distinct domains: an extracellular domain, a transmembrane domain, an intracellular domain, and a catalytic domain. The extracellular domain is the region of the protein that is involved in interactions with other cells and tissues. The transmembrane domain is the region that spans the membrane of the muscle cell and interacts with the cytoskeleton. The intracellular domain is the region that interacts with other proteins inside the muscle cell. The catalytic domain is the region that is responsible for the protein's catalytic activity.

ICA1L is involved in a number of cellular processes that are important for muscle function, including muscle and relaxation, muscle growth and development, and muscle repair. It is thought to be involved in the regulation of the myosin ATPase, a protein that is responsible for generating the energy that is required for muscle contraction.

In addition to its role in muscle function, ICA1L is also thought to be involved in the regulation of a number of other cellular processes that are important for brain development and function. It is thought to be involved in the regulation of the cytoskeleton, the cell membrane, and the release of neurotransmitters. It is also thought to be involved in the regulation of synaptic plasticity, the ability of the brain to change and adapt over time.

As a potential drug target, ICA1L is an attractive target for drug developers because of its involvement in a number of cellular processes that are important for health and disease. It is also thought to be involved in the regulation of a number of diseases, including ALS , which makes it an attractive target for drugs that can slow or stop the progression of ALS.

ICA1L is also a potential biomarker for ALS. The disease is often characterized by the progressive loss of motor neurons, which can be detected using a variety of tests, including muscle biopsy and neuroimaging techniques. By measuring the levels of ICA1L in muscle cells or tissue samples, it may be possible to diagnose ALS and monitor the effectiveness of treatments.

In conclusion, ICA1L is a protein that is expressed in various tissues and cells and is thought to contribute to the neurodegeneration that occurs in ALS. It is also a potential drug target and biomarker for the disease. Further research is needed to fully understand the role of ICA1L in ALS and to develop effective treatments.

Protein Name: Islet Cell Autoantigen 1 Like

The "ICA1L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ICA1L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets